Franklin Resources Inc. Lowers Position in Genmab A/S (NASDAQ:GMAB)

Franklin Resources Inc. decreased its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 5.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 25,663 shares of the company’s stock after selling 1,404 shares during the period. Franklin Resources Inc.’s holdings in Genmab A/S were worth $607,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GMAB. DDD Partners LLC purchased a new stake in shares of Genmab A/S during the 2nd quarter worth $8,860,000. Two Sigma Advisers LP lifted its position in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after buying an additional 280,900 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after buying an additional 145,689 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Genmab A/S during the 2nd quarter worth approximately $1,354,000. Institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial reduced their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Down 1.2 %

Shares of NASDAQ:GMAB opened at $20.77 on Tuesday. The business has a 50-day moving average price of $21.56 and a 200-day moving average price of $24.51. The stock has a market cap of $13.74 billion, a price-to-earnings ratio of 20.17, a PEG ratio of 0.67 and a beta of 0.96. Genmab A/S has a 52-week low of $19.85 and a 52-week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the previous year, the firm posted $0.47 earnings per share. As a group, equities analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.